Table 1. GI50 value of treatment on primary as well as cancer cell lines.
| Cell Name | SLCA A (μg ml-1) | SLCA B (μg ml-1) | SLCA C (μg ml-1) | SLCA D (μg ml-1) | SLCA E (μg ml-1) | SLCA F (μg ml-1) | aDoxorubicin (μg ml-1) | aPaclitaxel (μg ml-1) |
|---|---|---|---|---|---|---|---|---|
| HUVEC | > 320 | > 320 | > 320 | > 320 | > 320 | > 320 | >10 | >10 |
| THP-1 | > 320 | > 320 | > 320 | > 320 | > 320 | > 320 | >10 | 0.14±0.01 |
| L929 | > 320 | > 320 | > 320 | > 320 | > 320 | > 320 | >10 | >10 |
| HeLa | 191.87±2.31 | 16.32±3.81 | 14.14±3.76 | > 320 | 164.5±3.64 | > 320 | 1.45±0.45 | 0.005±0.00 |
| HCT 116 | 64.56±5.2 | 62.77±12.25 | 23.22±2.89 | > 320 | 103.08±4.29 | > 320 | 0.54±0.01 | 0.026±0.01 |
| A549 | 190.31±5.78 | 236.32±6.39 | 14.95±3.52 | > 320 | >320 | > 320 | 0.87±0.19 | 0.004±0.001 |
| MCF -7 | 239.76±6.36 | 65.7±3.38 | 37.71±5.44 | 248.93 | 255.15±3.81 | 256.86±6.86 | 2.52±0.43 | 0.002± |
| PANC-1 | > 320 | 113.52±4.66 | 116.33±5.35 | > 320 | > 320 | > 320 | 3.96±0.76 | 0.128±0.01 |
| A431 | > 320 | > 320 | > 320 | > 320 | > 320 | > 320 | 9.05±0.90 | 1.64±0.39 |
a Standard anticancer drug as a positive control.
The data represents mean ± SD of three independent experiments.